CONSENSUS STATEMENT

Molecular Basis of Connective Tissue and Muscle Injuries in Sport

Panel members:

Arne Ljungqvist (Sweden)  Chairman, IOC Medical Commission
Martin Schwellnus (South Africa)  Professor of Sports Science and Sports Medicine, University of Cape Town
Norbert Bachl (Austria)  Dean, Professor of Exercise Physiology, University of Vienna
Malcolm Collins (South Africa)  Specialist Scientist, South African Medical Research Council
Jill Cook (Australia)  Associate Professor, La Trobe University, Deakin University
Karim Khan (Canada)  Associate Professor, University of British Columbia, Vancouver
Nicola Maffulli (United Kingdom)  Professor of Trauma & Orthopaedics, Keele University School of Medicine, Stoke on Trent, UK
Yannis Pitsiladis (United Kingdom)  Reader in Exercise Physiology, Institute of Biomedical and Life Sciences, University of Glasgow
Graham Riley (United Kingdom)  Senior Research Fellow, Arthritis Research Campaign University of East Anglia, Norwich
Geoffrey Golspink (United Kingdom)  Professor, Royal Free and University College Medical School, London
Deon Venter (Australia)  Co-Director Pathology, Mater Health Services, Brisbane
Wayne Derman (South Africa)  Associate Professor, Sports Science & Sports Medicine, University of Cape Town
Lars Engebretsen (Norway)  Chairman, Orthopaedic Centre, University of Oslo
Piero Volpi (Italy)  MD IRCC- Galeazzi Orthopaedic Institute, Milan
Introduction

It is estimated that there are over 100 million musculoskeletal (tendon / muscle / bone) injuries annually worldwide. Of these, 30-50% constitute tendon and ligament injuries, which cause significant loss of performance in sport and decreased functional capacity in the workplace, and negatively impact on the ability of members of the general population to undertake exercise. A significant proportion of these injuries remain difficult to treat, and many individuals have long-term pain and discomfort.

The International Olympic Committee recently assembled an expert group to discuss the nature of the problem, the current state of the art and need for further research. Recent advances in this field relate to: (i) discovery of novel genetic markers for risk of tendon injury; (ii) improved understanding of structure and composition of tendon and its response to loading; (iii) increasing clinical use of growth factors to treat a variety of tendon, bone and muscle injuries; and (iv) research exploring the potential of applying stem cells to benefit patients with musculoskeletal problems. This consensus statement addresses each of these advances in more detail.

(i) Genetic predisposition to musculoskeletal injury

Musculoskeletal injuries have complex causes including both genetic and non-genetic factors. The search for genes that may predispose athletes to these injuries is gaining momentum, but remains in its infancy. For example, variants within two genes (which produce type V collagen and tenascin C) were recently discovered to be associated with Achilles tendon pain. Large studies in various populations using high-throughput technologies such as genomics and proteomics will be required to advance knowledge of genetic associations with musculoskeletal injuries. It will allow researchers to identify further genes that may be associated with these and other specific musculoskeletal injuries. The ability to identify people at-risk for these injuries will extend to the general population, where injury prevention will ensure that people can exercise appropriately for their inherited genetic makeup.

(ii) Structure and composition of tendon and its response to loading

When athletes experience tendon pain, structural abnormalities are already present. Under the microscope, inflammatory cells are generally absent at the site of injury. Hence the terms “tendinitis” or “tendonitis” have fallen out of favour. Injured tendon has several characteristic features such as increased or decreased cellularity and dramatic alteration in matrix structure and composition. There are quantitative and qualitative changes in collagen, proteoglycan, and matrix-degrading enzymes and increased penetration of blood vessels and nerves. A classical term to describe this overall appearance has been “tendinosis”, but the above features are consistent with inadequate repair – a failed healing response.

Although load is important to maintain the normal tendon matrix, pathology in tendons is often linked to overuse. Exercise can increase the production of collagen and other proteins in tendons, and thus can be used as part of the management of tendon injuries. Although tendon cells respond to load by increasing protein production, at this stage it is unclear what stimulus is required to restructure a damaged matrix. Chronic end stage tendon disease may never fully recover the normal matrix structure and composition, although adequate pain-free function is still possible.

(iii) Increasing clinical use of growth factors

Growth factors comprise a number of proteins which are secreted by cells. Numerous experimental studies have shown that growth factors are involved in bone and cartilage formation, fracture healing, tendon and ligament repair, and skeletal muscle regeneration. Therefore, it is not surprising that their therapeutic use is of enormous interest in the field of sports medicine, and in helping treat workplace-related injuries. Growth factors of current interest include Growth Hormone (GH), Insulin-like Growth Factor-1 (IGF-1), Mechano Growth Factor (MGF), Basic Fibroblast Growth Factor (B-FGF), Platelet-derived Growth Factor (PDGF), Vascular Endothelial Growth Factor (VEGF), Transforming Growth Factor – β (TGF-β) and Bone Morphogenic Protein (BMP) (see Appendix 1). Several of these growth factors are currently commercially available, and are used successfully in clinical settings.
BMPs have proved to be efficient during different stages of the bone healing process in various animal and human models. VEGF, PDGF, FGF and TGF-β have also been shown to play an important role in ligament and tendon healing. Although a body of research evidence exists in animal models, with the exception of BMPs, the results of late stage randomised controlled human clinical studies are as-yet unavailable, and the long-term local and systemic effects of these agents are unknown. FGFs, TGF-β and PDGF have been shown to be important in the muscle regeneration process. VEGF as well as PDGF have been shown to increase blood flow to skeletal muscle. However, the administration of VEGF to improve blood perfusion was investigated in other clinical studies with limited success, whereas a phase II trial of PDGF revealed positive effects on peripheral blood flow.

Many fractures do not heal properly, and there is therefore still a need for augmentation of the bone healing process. Recombinant human bone morphogenetic protein 2 (rhBMP-2) and recombinant human bone morphogenetic protein 7 (rhBMP-7) or osteogenic protein 1 (OP-1) has so far been used clinically. At present, there are several published clinical studies on the effects of BMPs in bone healing or in delayed unions/non-unions and several studies have reported the effects in fusion of the lumbar spine, to the point where this now constitutes a well-established practice in orthopaedic surgery.

Growth hormone, produced by the pituitary, induces the liver to produce systemic IGF-1, which forms a tripartite binding complex with IGF binding protein three (IGFBP-3) and the acid labile subunit (ALS), to stabilise IGF-1 in the serum. The levels of GH and IGF-1 reach their peak levels during adolescence. With increasing age, however, there is a marked decline in the circulating levels of GH and a somewhat smaller decline in circulating IGF-1. Treatment of GH-deficient adults for an extended period of time results in not only increased muscle strength but also decreased body fat. These findings have encouraged the illicit use of GH and GH-like substances among athletes, even those competing at secondary school level, to attempt to enhance performance. This provides an ongoing problem for Anti-Doping Agencies. At present, there are methods for detecting GH and GH-like substances, as well as systemic IGFs. However the situation is complicated by local forms of IGF-1, such as mechano growth factor (MGF), that are not detectable using current methods. MGF is produced after exercise by the splicing of the IGF-1 gene and it has a different sequence to the systemic type of IGF-1. It is very potent for increasing muscle mass and strength. MGF apparently acts as a separate growth factor that is involved in activating satellite cell proliferation and replenishing the pool of these muscle stem cells. In summary, these animal model studies have highlighted some interesting candidates that await evaluation in human clinical trials.

**(iv) Research exploring the potential of applying stem cells**

Mesenchymal stem cells (MSCs) are adult tissue-producing cells that have been isolated from various parts of the body, including cartilage, bone marrow, synovium, adipose tissue, articular cartilage, muscle and tendons. Presently, MSCs can potentially be used for tissue engineering strategies through implantation of scaffolds and gels, for gene delivery, and for growth factor production to stimulate tissue repair or inhibit tissue degradation. Whilst most studies have been conducted in animal models, some studies of human bone, cartilage and tendons have produced positive results. However, further controlled clinical trials in musculoskeletal injuries in humans are warranted. A reason for the lack of progress in this field includes finding the optimal sources of and methods for the differentiation of cells, and the development of optimal surgical delivery materials and methods. Whilst some studies have shown negative effects, including ectopic calcification and connective tissue overgrowth, further clinical trials should be undertaken to determine whether long-term complications exist.

**Possible future research directions in growth factor therapy**

The implementation of new biological therapies based on the administration of growth factors and the manipulation of adult stem cells will require an improved understanding of the genetic regulatory networks affected by these agents. This will be necessary for two reasons: first, in order to ensure that these therapies are optimised, and, secondly, in order to ensure patient/athlete safety. Knowledge of the genomic and proteomic impacts of growth factor-based therapies on the target cells, and of the biomarkers reflecting stem cell differentiation status, will underpin the development of tests capable of monitoring therapeutic efficacy and minimising adverse events.
Potential for misuse of growth factors and cell-based therapies
The ability to manipulate existing muscle cells and muscle stem cells has the potential for use in the context of illegal performance enhancement. Knowledge of the underlying genetic and cellular events impacted on by growth factor administration can be used to develop tests capable of detecting the illegal use of such technologies for performance enhancement. The IOC will monitor developments in this field to ensure that such practices are discouraged, and detected if used, by working with the anti-doping agencies.

Scientific advisors
The IOC now has high-level scientific advisors who are capable of monitoring new developments in the field of growth factor and cell-based therapies, and of advising these bodies in relation to the use and abuse of these technologies. These advisors will help ensure that athletes and coaches receive the benefits of these developments in improving their ability to prevent injury, and to enhance therapy if injured. In addition, the illegal use of these technologies in the field of performance enhancement will be increasingly difficult as methods of detecting such use become available.
Recommended reading


<table>
<thead>
<tr>
<th>Muscle</th>
<th>Cartilage</th>
<th>Tendon/Ligament</th>
<th>Bone</th>
</tr>
</thead>
<tbody>
<tr>
<td>GH</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>IGF-1</td>
<td>++</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>MGF</td>
<td>+++</td>
<td>?</td>
<td>+</td>
</tr>
<tr>
<td>bFGF</td>
<td>+</td>
<td>+</td>
<td>+/-</td>
</tr>
<tr>
<td>PDGF</td>
<td>-</td>
<td>+/-</td>
<td>+/-</td>
</tr>
<tr>
<td>VEGF</td>
<td>+</td>
<td>+/-</td>
<td>+/-</td>
</tr>
<tr>
<td>TGF-β</td>
<td>+/-</td>
<td>+</td>
<td>+/-</td>
</tr>
<tr>
<td>BMP-2</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

Appendix 1: Summary of growth factor expression in musculoskeletal tissues